Compare UiPath Inc (PATH) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Tempus AI — how do they compare? UiPath Inc trades at $13.26 (market cap $6.81B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Tempus AI is the larger of the two by market cap, and Tempus AI is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Tempus AI for 22 Days on average.
| PATH | TEM | |
|---|---|---|
Market Cap | $6.81B | $12.77B |
Volume | 22,766,109 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $19.29 | $99.28 |
52-Week Low | $9.38 | $41.55 |
Typical Hold Time | 139 Days | 22 Days |
Enterprise Value | $5.61B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.25, up 1.15% with mixed technical signals showing bearish momentum but neutral oscillators. The company demonstrates improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though the stock faces near-term headwinds from valuation concerns and competitive pressures.
PATH presents a turnaround story with strong revenue growth and path to profitability, but faces execution risks amid competitive automation landscape. The consensus price target of $15.13 suggests 14% upside potential, though technical weakness and mixed analyst sentiment warrant caution. Key catalysts include AI platform adoption and enterprise expansion, while risks involve growth sustainability and margin pressures.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
